```
=> d his

     (FILE 'HOME' ENTERED AT 14:50:33 ON 09 SEP 2005)

     FILE 'REGISTRY' ENTERED AT 14:50:43 ON 09 SEP 2005
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS
L3           0 S L1 SSS FULL
L4             STRUCTURE UPLOADED
L5           0 S L4 SSS
L6           5 S L4 SSS FULL
L7             STRUCTURE UPLOADED
L8           0 S L7 SSS
L9           1 S L7 SSS FULL
L10            STRUCTURE UPLOADED
L11          0 S L10 SSS
L12          1 S L10 SSS FULL
L13            STRUCTURE UPLOADED
L14          0 S L13 SSS
L15          5 S L13 SSS FULL

     FILE 'CAPLUS' ENTERED AT 15:01:49 ON 09 SEP 2005
L16          2 S L6 OR L9 OR L12 OR L15

=> d l1
L1 HAS NO ANSWERS
L1             STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> d bib abs hitstr 1-2

L16  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:550750  CAPLUS
DN   141:87914
TI   Antibiotics Cyan-416A, Cyan-416B, Cyan-416C, Cyan-416D, and Cyan-416E, and
     ester derivatives of Cyan-416B
IN   He, Haiyin; Bigelis, Ramunas
PA   Wyeth Holdings Corporation, USA
SO   U.S. Pat. Appl. Publ., 30 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   US 2004132812        A1    20040708    US 2003-736425         20031215
PRAI US 2002-434004P      P     20021217
OS   MARPAT 141:87914
AB   The invention relates to new antibiotics designated Cyan-416A, Cyan 416B,
     Cyan-416C, Cyan-416D and Cyan-416E to their production by fermentation of
Acremonium
     sp.  NRRL 30631 to methods for recovery and concentration from the crude
solns.,
     and to a process for purification and to semisynthetic ethers of Cyan-416B.
IT   701914-77-4P, Cyan 416A
     RL: BMF (Bioindustrial manufacture); BSU (Biological study, unclassified);
     CPS (Chemical process); PEP (Physical, engineering or chemical process);
     PRP (Properties); PUR (Purification or recovery); RCT (Reactant); BIOL
```

(Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(antibiotics cyan-416A, cyan-416B, cyan-416C, cyan-416D, and cyan-416E, and ester derivs. of cyan-416B)

RN 701914-77-4 CAPLUS

CN Benzoic acid, 2-[[(5aR,6S,13S)-6-(acetyloxy)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-3,6-dihydroxy-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



IT **701914-78-5DP**, Cyan 416B, and esters of
RL: BSU (Biological study, unclassified); CPS (Chemical process); IMF (Industrial manufacture); PEP (Physical, engineering or chemical process); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
(antibiotics cyan-416A, cyan-416B, cyan-416C, cyan-416D, and cyan-416E, and ester derivs. of cyan-416B)

RN 701914-78-5 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,6,10,11-pentahydroxy-8-methyl-12-oxo-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



IT **701914-82-1P**, Cyan 416B butyrate **701914-83-2P**, Cyan 416B isobutyrate **701914-84-3P**, Cyan 416B pentanoate
701914-85-4P, Cyan 416B hexanoate
RL: IMF (Industrial manufacture); PREP (Preparation)
(antibiotics cyan-416A, cyan-416B, cyan-416C, cyan-416D, and cyan-416E,

and ester derivs. of cyan-416B)

RN 701914-82-1 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-6-(1-oxobutoxy)-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



RN 701914-83-2 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-6-(2-methyl-1-oxopropoxy)-12-oxo-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



RN 701914-84-3 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-6-[(1-oxopentyl)oxy]-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



RN 701914-85-4 CAPLUS
CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-6-[(1-oxohexyl)oxy]-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:949247 CAPLUS
DN 141:36024
TI Acremonidins, new polyketide-derived antibiotics produced by Acremonium sp., LL-Cyan 416
AU He, Haiyin; Bigelis, Ramunas; Solum, Eric H.; Greenstein, Michael; Carter, Guy T.
CS Natural Products Research, Chemical and Screening Sciences, Wyeth Research, Pearl River, NY, 10965, USA
SO Journal of Antibiotics (2003), 56(11), 923-930
CODEN: JANTAJ; ISSN: 0021-8820
PB Japan Antibiotics Research Association
DT Journal
LA English
AB Acremonidins A, B and acremonidins C, D were produced by fermentation of Acremonium sp., LL-Cyan 416, in heterogeneous phases. The structures of these compds., containing a bridging keto group, were determined by spectroscopic
anal. Acremonidins A and Acremonidins B showed moderate activity against Gram-pos. bacteria, including the methicillin-resistant staphylococci and vancomycin-resistant enterococci. Acremonidins C, Acremonidins D, and acremonidin C were also active against Gram-pos. bacteria. Selective acylations of Acremonidins B afforded ester derivs. that exhibited improved antibacterial activity.
IT **701914-78-5P**, Acremonidin B

RL: BMF (Bioindustrial manufacture); NPO (Natural product occurrence); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(acremonidins are new polyketide-derived antibiotics produced by Acremonium LL-Cyan 416)

RN 701914-78-5 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,6,10,11-pentahydroxy-8-methyl-12-oxo-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



IT **701914-77-4P**, Acremonidin A
RL: BMF (Bioindustrial manufacture); NPO (Natural product occurrence); PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
(acremonidins are new polyketide-derived antibiotics produced by Acremonium LL-Cyan 416)

RN 701914-77-4 CAPLUS

CN Benzoic acid, 2-[[(5aR,6S,13S)-6-(acetyloxy)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-3,6-dihydroxy-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



IT **701914-82-1P**, Acremonidin B butyrate **701914-83-2P**, Acremonidin B isobutyrate **701914-84-3P**, Acremonidin B pentanoate **701914-85-4P**, Acremonidin B hexanoate

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antibacterial activity of)

RN 701914-82-1 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-6-(1-oxobutoxy)-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



RN 701914-83-2 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-6-(2-methyl-1-oxopropoxy)-12-oxo-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



RN 701914-84-3 CAPLUS

CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-6-[(1-oxopentyl)oxy]-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



RN 701914-85-4 CAPLUS
CN Benzoic acid, 3,6-dihydroxy-2-[[(5aR,6S,13S)-5,6,12,13-tetrahydro-1,3,10,11-tetrahydroxy-8-methyl-12-oxo-6-[(1-oxohexyl)oxy]-5a,13-etheno-5aH-benzo[4,5]cyclohepta[1,2-b]naphthalen-2-yl]carbonyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Currently available stereo shown.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>